Carme Font

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4094283/publications.pdf

Version: 2024-02-01

471509 276875 1,756 43 17 41 citations h-index g-index papers 50 50 50 1814 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Supportive Care in Cancer, 2022, 30, 2919-2931.	2.2	8
2	Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Supportive Care in Cancer, 2022, 30, 8599-8609.	2.2	5
3	Thrombosis, cancer, and COVID-19. Supportive Care in Cancer, 2022, 30, 8491-8500.	2.2	10
4	Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care. Supportive Care in Cancer, 2022, , 1.	2.2	1
5	Edoxaban for the Longâ€√erm Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0
6	Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Supportive Care in Cancer, 2021, 29, 1129-1138.	2,2	20
7	Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis. Cancers, 2021, 13, 2517.	3.7	3
8	Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry. British Journal of Haematology, 2021, 194, 195-199.	2.5	6
9	Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Internal and Emergency Medicine, 2021, , 1.	2.0	1
10	Mortality in patients treated for COVID-19 in the emergency department of a tertiary care hospital during the first phase of the pandemic: Derivation of a risk model for emergency departments. Emergencias, 2021, 33, 273-281.	0.6	2
11	A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study. Cancers, 2020, 12, 75.	3.7	20
12	High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. European Journal of Cancer, 2020, 141, 193-198.	2.8	15
13	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). Blood Advances, 2020, 4, 2460-2467.	5.2	7
14	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq0 0 0 rgBT / 2019, 45, 793-801.	Overlock 2.7	10 Tf 50 227 ¹
15	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
16	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. Scientific Reports, 2019, 9, 20064.	3.3	5
17	Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. Thrombosis and Haemostasis, 2018, 118, 1119-1122.	3.4	4
18	Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS). Supportive Care in Cancer, 2018, 26, 3233-3239.	2.2	25

#	Article	IF	Citations
19	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	1.7	6
20	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. TH Open, 2018, 02, e210-e217.	1.4	7
21	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS ONE, 2018, 13, e0194673.	2.5	16
22	Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. Critical Reviews in Oncology/Hematology, 2017, 113, 83-89.	4.4	45
23	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon, 2017, 3, e00229.	3.2	19
24	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. European Respiratory Journal, 2017, 49, 1600282.	6.7	52
25	Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. European Journal of Radiology, 2017, 87, 66-75.	2.6	9
26	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. American Journal of Medicine, 2017, 130, 337-347.	1.5	83
27	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937.	1.8	17
28	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Medicine (United States), 2016, 95, e2368.	1.0	55
29	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. European Respiratory Journal, 2016, 48, 1360-1368.	6.7	21
30	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. British Journal of Cancer, 2016, 114, 1191-1198.	6.4	14
31	Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study Journal of Clinical Oncology, 2015, 33, 9617-9617.	1.6	0
32	Outpatient Management of Pulmonary Embolism in Cancer: Data on a Prospective Cohort of 138 Consecutive Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 365-373.	4.9	38
33	A nomogram for predicting serious complications in patients with solid tumors and apparently stable febrile neutropenia: Prospective data on 781 consecutive episodes from the FINITE study Journal of Clinical Oncology, 2014, 32, 165-165.	1.6	1
34	Prediction of major complications in patients with solid tumors and apparently stable febrile neutropenia: Validation of the CISNE risk score Journal of Clinical Oncology, 2014, 32, 9620-9620.	1.6	0
35	Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study Journal of Clinical Oncology, 2014, 32, 9526-9526.	1.6	0
36	Solid cancer, antiphospholipid antibodies, and venous thromboembolismâ ⁻ †. Autoimmunity Reviews, 2011, 10, 222-227.	5.8	33

#	Article	IF	CITATION
37	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. Circulation, 2002, 106, 1664-1671.	1.6	99
38	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. Arthritis and Rheumatism, 2001, 44, 1387-1395.	6.7	105
39	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis and Rheumatism, 2000, 43, 184-194.	6.7	128
40	Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis and Rheumatism, 1998, 41, 26-32.	6.7	255
41	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis and Rheumatism, 1998, 41, 435-444.	6.7	56
42	Reply. Arthritis and Rheumatism, 1998, 41, 2088-2089.	6.7	5
43	Large vessel vasculitides. Current Opinion in Rheumatology, 1998, 10, 18-28.	4.3	78